<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Calgary_Safety skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Calgary/Safety</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><BUTTON onclick="topFunction()" id="topBtn" title="Go to top">TOP</BUTTON></P><DIV class="collapse navbar-collapse" id="navbarNavDropdown"><UL class="navbar-nav"><LI class="nav-item dropdown"><A class="nav-link underline-animation" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        Project
                    </A><DIV class="dropdown-menu dropdown-menu-center" aria-labelledby="navbarDropdownMenuLink"><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Description">Description</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/CRISPR">CRISPR</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/FLP-Beta">FLP-Beta</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Chromatin_Modifying_Elements">CME</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Applied_Design">Product Design</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Model">Modelling</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Software">Software</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Results">Results</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link underline-animation" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        Notebook
                    </A><DIV class="dropdown-menu dropdown-menu-center" aria-labelledby="navbarDropdownMenuLink"><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Notebook">Journals</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Protocols">Protocols</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link underline-animation" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        Team
                    </A><DIV class="dropdown-menu dropdown-menu-center" aria-labelledby="navbarDropdownMenuLink"><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Team">Team Members</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Attributions">Attributions</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Sponsors">Sponsors</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Contact_Us">Contact Us</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link underline-animation" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        Human Practices
                    </A><DIV class="dropdown-menu dropdown-menu-center" aria-labelledby="navbarDropdownMenuLink"><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Human_Practices">Summary</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Human_Practices/Silver">Silver</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Human_Practices/Gold_Integrated">Integrated</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Collaborations">Collaborations</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Public_Engagement">Public Engagement</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Safety">Safety</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link underline-animation" href="#" id="navbarDropdownMenuLink" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        Judging
                    </A><DIV class="dropdown-menu dropdown-menu-center" aria-labelledby="navbarDropdownMenuLink"><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/MedalRequirements">Medal Requirements</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Parts">Parts</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/Improve">Improved Part</A><A class="dropdown-item" href="https://2018.igem.org/Team:Calgary/InterLab">Interlab</A></DIV></LI></UL></DIV><P><TITLE>Team:Calgary/Safety - 2018.igem.org</TITLE></P><DIV class="container maincontent"><H1 style="transform: translateY(-50%)" class="infotitle">SAFETY</H1><DIV class="infosection"><H3 class="infosubtitle">Safety and Ethical Risks</H3><P style="text-indent: 0px">Our gene integration strategy was designed for use in existing ex vivo gene
                transfer processes to mediate targeted integration. The immediate use case is constrained to research
                projects in lab environments, however the strategy could hypothetically also be used eventually in gene
                therapies to correct recessive genetic diseases by integrating DNA encoding for the wild type,
                functional protein. The system could, with little modification, be used to integrate arbitrarily large
                DNA constructs into virtually any genome. The risks of this enablement are extensive, but do not
                greatly exceed existing gene transfer technologies. The off-target activity of CRISPR/Cas9 is well
                established, and may result in the integration of the transgenic construct outside of the targeted
                genomic safe harbour. However, such risk is negligible compared to the pseudorandom integration typical
                of virus-mediated integration. Although the strategy may be appropriate for eventual use in human gene
                therapy, that potential is beyond the scope of our work. Further evaluations and investigations into
                the ethical risks of our project can be seen on our <A class="info-link" href="https://2018.igem.org/Team:Calgary/Human_Practices/Gold_Integrated">Integrated Human Practices
   </A> page.</P><H3 class="infosubtitle">Safety in the Lab</H3><P style="text-indent: 0px">Before beginning work in the lab, all team members, mentors, and Principal
                Investigators completed lab safety courses developed by the <A class="info-link" href="https://www.ucalgary.ca/safety/" target="“_blank”">University of Calgary Environment Health and Safety (EHS)</A> services. The courses
                covered a wide range of topics such as occupational health and safety, laboratory safety, hazard
                assessment, incident reporting and investigation, spill response, biosafety, bloodborne pathogens, and
                WHMIS. The completion of these courses ensured that everyone on the team worked safely in the lab and
                could respond to incidents or hazards appropriately. Furthermore, the <A class="info-link" href="https://www.ucalgary.ca/safety/health-safety-committees/biosafety" target="“_blank”">University of Calgary Biosafety Committee</A> outlines guidelines for safe
                biological laboratory practices. These guidelines were observed and adhered to during all of our
                experimental work.</P><P style="text-indent: 0px">Our project used a common lab strain of <I>Escherichia coli</I>, DH5-alpha.
                This strain is non-pathogenic and is classified as Biosafety Level 1 (BSL-1), therefore its use posed
                low risk to researchers. We also used an immortalized human cell line, HEK293T cells, which are Risk
                Group 1 organisms. HEK293T cells have adenovirus genetic contents and Simian Virus 40 large T antigen
                (SV40T), however, these cells do not contain the complete viral genomes, therefore the risk of viral
                particle generation by these cells is low (ATCC, 2016). The cells are not themselves infectious, are
                not known to carry any disease-causing agents, and are virtually unable to survive outside of the lab.
                All experiments with HEK293T cells was done in a BSL-2 Biosafety Cabinet to ensure the safety of
                researchers and to work within University of Calgary safety guidelines. Our lab is a certified BSL-2
                lab, therefore it was equipped for safe work with both <I>E. coli</I> DH5-alpha and HEK293T cells.</P><DIV class="apa-reference"><H4 style="text-align: center">WORKS CITED</H4><P>ATCC - American Type Culture Collection. (2016). 293T (ATCC CRL-3216). Retrieved from <A class="info-link" href="https://www.atcc.org/products/all/CRL-3216.aspx#generalinformation" target="blank">https://www.atcc.org</A>.</P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>